AVANADE
7.9.2021 11:24:14 CEST | Business Wire | Press release
Avanade , the leading digital innovator on the Microsoft ecosystem, today announced the launch of its business in the United Arab Emirates (UAE), with offices in Dubai and Abu Dhabi. Adriano Neves, Avanade’s Sales, Industry and Client Relationships Lead in Brazil, has been appointed to lead the company’s newest entity and will relocate from São Paulo to Dubai.
Established by Accenture and Microsoft in 2000, Avanade today has 49,000 professionals globally focused on the Microsoft ecosystem providing technology and consulting expertise to help clients from across industries including financial services, oil and gas, and citizen services. Avanade’s presence in the United Arab Emirates represents the 26th country location in the company’s expanding global footprint.
Leveraging its global delivery network, technical depth and Microsoft-focused capabilities, Avanade will work with Accenture to jointly help clients in the UAE create exceptional experiences, build operational resilience and reimagine new business models. In the recently published “IDC MarketScape: Worldwide Microsoft Implementation Services 2021 Vendor Assessment ,” Accenture and Avanade have been jointly recognized as a leader based on current capabilities and future strategies. Together, Accenture and Avanade have been named Microsoft Global Alliance SI Partner of the Year 16 times , more than any other partner.
Adriano Neves, Avanade’s United Arab Emirates regional lead, said: “As organizations renew for the future, we want to make a positive impact in the region by helping our clients solve complex business problems that are unique to their industries and realize their business goals faster on the Microsoft platform.”
Nadya Abdulla Kamali, Accenture’s country managing director for the UAE, said: “We are thrilled to welcome Avanade to the United Arab Emirates. With our combined service capabilities, global scale and joint solution development on the Microsoft platform, we look forward to helping our clients drive an end-to-end digital transformation of their businesses.”
Sayed Hashish, General Manager, Microsoft UAE added: “Our partnership with Accenture through Avanade has grown tremendously, and the launch of Avanade in the United Arab Emirates marks another milestone for our successful collaboration. Together with Avanade and Accenture, we will continue to empower every person and organization in the UAE to achieve more.”
To fuel the company’s ambitious growth, Avanade is recruiting digital, IT and consulting specialists who have a passion for Microsoft platform technologies. Interested individuals are encouraged to apply for open roles here: https://www.avanade.com/en/career
About Adriano Neves, United Arab Emirates Regional Lead, Avanade
Based in Dubai, Adriano Neves leads a team of digital professionals focused on powering the Accenture Microsoft Business Group and helping enterprises realize business outcomes on the Microsoft platform. Prior to his current role, Adriano was responsible for Avanade’s Sales, Industry and Client Relationships in Brazil focused on delivering exceptional experiences and making a genuine human impact for clients. As one of Avanade’s first employees in Brazil, Adriano played a pivotal role in partnering with Accenture and Microsoft to not only establish Avanade’s business and market presence in the region, but to build the most relevant Microsoft partner in the region. Before he joined Avanade, Adriano spent nearly 10 years in a variety of leadership roles at Microsoft Brazil. In his spare time, Adriano volunteers as a business advisor to startups.
About Accenture
Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 569,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at www.accenture.com .
About Avanade
Avanade is the leading provider of innovative digital and cloud services, business solutions and design-led experiences on the Microsoft ecosystem. Our professionals bring bold, fresh thinking combined with technology, business and industry expertise to help make a genuine human impact for our clients, their customers and their employees. We are the power behind the Accenture Microsoft Business Group, helping companies to engage customers, empower employees, optimize operations and transform products, leveraging the Microsoft platform. Avanade has 49,000 professionals in 26 countries, bringing clients our best thinking through a collaborative culture that honors diversity and reflects the communities in which we operate. Majority owned by Accenture, Avanade was founded in 2000 by Accenture LLP and Microsoft Corporation. Learn more at www.avanade.com .
About Microsoft
Microsoft (Nasdaq “MSFT” @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.
*Source : AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005412/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom